Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Medication: Integrative and Nutrition Therapies for Disorders of Gut-Brain Interaction.

Gastroenterology & hepatology·2026
Same author

A Primer for Discussing Complementary and Integrative Medicine in Gastroenterology Settings.

Neurogastroenterology and motility·2026
Same author

Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus.

The American journal of gastroenterology·2026
Same author

On the Correlation Between Gastrointestinal Symptoms and Sites for Endoscopic Biopsies to Diagnose Graft-Versus-Host Disease.

Clinical and translational gastroenterology·2025
Same author

Exercise-Induced Colon Ischemia in a Middle-Aged Female Athlete: Response to a Novel Therapeutic Approach of Sildenafil and Fludrocortisone.

ACG case reports journal·2025
Same author

Retrograde Examination of the Rectum Is a Bad Thing to Do.

Gastro hep advances·2024

Related Experiment Video

Updated: Jul 15, 2026

Multimodality Diagnosis of Mesenteric Ischemia
05:07

Multimodality Diagnosis of Mesenteric Ischemia

Published on: July 21, 2023

Pharmacologically mediated colon ischemia.

David J Hass1, Patricia Kozuch, Lawrence J Brandt

  • 1Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York 10467, USA.

The American Journal of Gastroenterology
|May 10, 2007
PubMed
Summary

Colon ischemia (CI) is a common gastrointestinal issue, often challenging to diagnose. This review highlights pharmacologically induced alterations in colonic blood flow as a key, often overlooked, cause of CI.

More Related Videos

Murine Model of Intestinal Ischemia-reperfusion Injury
07:07

Murine Model of Intestinal Ischemia-reperfusion Injury

Published on: May 11, 2016

Related Experiment Videos

Last Updated: Jul 15, 2026

Multimodality Diagnosis of Mesenteric Ischemia
05:07

Multimodality Diagnosis of Mesenteric Ischemia

Published on: July 21, 2023

Murine Model of Intestinal Ischemia-reperfusion Injury
07:07

Murine Model of Intestinal Ischemia-reperfusion Injury

Published on: May 11, 2016

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Vascular Medicine

Background:

  • Colon ischemia (CI) is the most frequent ischemic injury affecting the gastrointestinal tract.
  • Accurate incidence determination is difficult due to mild, transient symptoms, spontaneous resolution, and misdiagnosis.
  • Underlying conditions predispose to CI, but pharmacologic factors are a significant, underrecognized etiology.

Purpose of the Study:

  • To review pharmacologic agents associated with colon ischemia.
  • To elucidate the mechanisms of action for drug-induced CI.
  • To raise physician awareness of this etiology to improve prompt diagnosis and patient outcomes.

Main Methods:

  • Comprehensive literature review of pharmacologic agents linked to colon ischemia.
  • Analysis of documented mechanisms of action for drug-induced CI.
  • Synthesis of information to highlight clinical relevance for healthcare providers.

Main Results:

  • Identified and detailed various pharmacologic agents implicated in causing CI.
  • Described the proposed mechanisms by which these agents affect colonic blood flow.
  • Emphasized the importance of considering medication side effects in CI diagnosis.

Conclusions:

  • Pharmacologically induced alterations in colonic blood flow represent a critical, often overlooked, cause of CI.
  • Increased physician awareness of drug-associated CI can lead to earlier recognition and intervention.
  • Prompt diagnosis and management can potentially reduce CI-related morbidity and mortality.